NervGen Pharma Corp. Common stock
NGEN
Get informed when a big investor buys or sells
+ FollowMarket Cap$187.4M
Close$
$0.22
90.6% downside
Current Fair Value
90.6% downsideOvervalued by 90.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $187.40 Million |
|---|---|
| Enterprise Value | $100.47 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.61 |
| Beta | 0.71 |
| Outstanding Shares | 92,443,523 |
Return
| Return on Equity | -390.39% |
|---|---|
| Return on Assets | -74.79% |
| Return on Invested Capital | -67.48% |
Valuation & Multiples
| P/E Ratio | -8.41 |
|---|---|
| PEG | -3.69 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -8.6 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
$4,500
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.12%▲ 2.11% |
|---|---|
| Total Invested | $6.42M▲ 11370.34% |
| Investors Holding | 45▲ 44.00% |
ESG Score
No data
About NervGen Pharma Corp. Common stock
8 employees
CEO: Adam H. Rogers NervGen Pharma Corp. is a biotechnology enterprise currently in its clinical development phase, focused on devising therapeutic solutions for nerve injuries and progressive neurodegenerative diseases. Their innovative approach centers on...